Weighed down by safe­ty con­cerns of JAK port­fo­lio, Pfiz­er hatch­es a deal to go a dif­fer­ent di­rec­tion in rheuma­toid arthri­tis

Days af­ter con­ced­ing that its block­buster JAK in­hibitor flunked a post-mar­ket­ing safe­ty study, Pfiz­er has signed off on a brand new ap­proach to rheuma­toid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.